JP2010518167A5 - 併存する早漏及び勃起障害を治療するための治療剤、製薬組成物及びキット - Google Patents
併存する早漏及び勃起障害を治療するための治療剤、製薬組成物及びキット Download PDFInfo
- Publication number
- JP2010518167A5 JP2010518167A5 JP2009549684A JP2009549684A JP2010518167A5 JP 2010518167 A5 JP2010518167 A5 JP 2010518167A5 JP 2009549684 A JP2009549684 A JP 2009549684A JP 2009549684 A JP2009549684 A JP 2009549684A JP 2010518167 A5 JP2010518167 A5 JP 2010518167A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- tramadol
- pharmaceutically acceptable
- pde5
- acceptable form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims 9
- 229940124597 therapeutic agent Drugs 0.000 title claims 9
- 208000010228 Erectile Dysfunction Diseases 0.000 title claims 3
- 201000001881 impotence Diseases 0.000 title claims 3
- 206010036596 premature ejaculation Diseases 0.000 title claims 3
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 21
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 21
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 20
- 229960004380 tramadol Drugs 0.000 claims 17
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 17
- 239000000463 material Substances 0.000 claims 14
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 8
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 8
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 7
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 6
- 229960002639 sildenafil citrate Drugs 0.000 claims 6
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 claims 6
- 229960000835 tadalafil Drugs 0.000 claims 6
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 4
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 claims 3
- FBCDRHDULQYRTB-UHFFFAOYSA-N 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1h-imidazo[5,1-f][1,2,4]triazin-4-one;trihydrate;hydrochloride Chemical compound O.O.O.Cl.CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 FBCDRHDULQYRTB-UHFFFAOYSA-N 0.000 claims 3
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 3
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 claims 3
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 claims 3
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 3
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 3
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims 3
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 claims 3
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 3
- 229960003310 sildenafil Drugs 0.000 claims 3
- 229960002381 vardenafil Drugs 0.000 claims 3
- 229960001540 vardenafil hydrochloride Drugs 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
Images
Claims (19)
- ヒト男性における早漏と勃起障害との併存状態を治療するための治療剤であって、性的行為の前の効果的な時間に投与される治療剤において、前記治療剤は、
有効量のトラマドール材料と有効量のホスホジエステラーゼ（ＰＤＥ）阻害剤とからなる、治療剤。 - 前記トラマドール材料は、トラマドール又はその製薬的に許容される形態であり、ＰＤＥ阻害剤は、ＰＤＥ３、ＰＤＥ４又はＰＤＥ５阻害剤である、請求項１に記載の治療剤。
- 前記ＰＤＥ阻害剤は、ＰＤＥ５阻害剤である、請求項２に記載の治療剤。
- 前記トラマドール材料は（±）シス−トラマドール又はその製薬的に許容される形態であり、前記ＰＤＥ５阻害剤はシルデナフィル又はその製薬的に許容される形態、バルデナフィル又はその製薬的に許容される形態、タダラフィル又はその製薬的に許容される形態、或いは前記ＰＤＥ５阻害剤の二つ以上の組み合わせである、請求項３に記載の治療剤。
- 前記トラマドール材料は（±）シス−トラマドール塩酸塩であり、かつ前記ＰＤＥ５阻害剤はクエン酸シルデナフィル、バルデナフィル塩酸塩、タダラフィル、或いは前記ＰＤＥ５阻害剤の二つ以上の組み合わせである、請求項４に記載の治療剤。
- 前記ＰＤＥ５阻害剤はクエン酸シルデナフィルである、請求項５に記載の治療剤。
- 製薬的に許容される担体と、トラマドール材料と、ホスホジエステラーゼ（ＰＤＥ）阻害剤と、からなる製薬組成物。
- 前記トラマドール材料は、トラマドール又はその製薬的に許容される形態であり、ＰＤＥ阻害剤は、ＰＤＥ３、ＰＤＥ４又はＰＤＥ５阻害剤である、請求項７に記載の組成物。
- 前記ＰＤＥ阻害剤は、ＰＤＥ５阻害剤である、請求項８に記載の組成物。
- 前記トラマドール材料は（±）シス−トラマドール又はその製薬的に許容される形態であり、前記ＰＤＥ５阻害剤はシルデナフィル又はその製薬的に許容される形態、バルデナフィル又はその製薬的に許容される形態、タダラフィル又はその製薬的に許容される形態、或いは前記ＰＤＥ５阻害剤の二つ以上の組み合わせである、請求項９に記載の組成物。
- 前記トラマドール材料は（±）シス−トラマドール塩酸塩であり、かつ前記ＰＤＥ５阻害剤はクエン酸シルデナフィル、バルデナフィル塩酸塩、タダラフィル、或いは前記ＰＤＥ５阻害剤の二つ以上の組み合わせである、請求項１０に記載の組成物。
- 前記ＰＤＥ５阻害剤はクエン酸シルデナフィルである、請求項１１に記載の組成物。
- （ａ）トラマドール材料と、ホスホジエステラーゼ（ＰＤＥ）阻害剤と、を保持する容器、或いは
（ｂ）トラマドール材料を保持する第一の容器及びホスホジエステラーゼ（ＰＤＥ）阻害剤を保持する第二の容器、
からなる、キット。 - 前記トラマドール材料はトラマドール又はその製薬的に許容される形態であり、ＰＤＥ阻害剤は、ＰＤＥ３、ＰＤＥ４又はＰＤＥ５阻害剤である、請求項１３に記載のキット。
- 前記ＰＤＥ阻害剤はＰＤＥ５阻害剤である、請求項１４に記載のキット。
- 前記トラマドール材料は（±）シス−トラマドール又はその製薬的に許容される形態であり、かつ、前記ＰＤＥ５阻害剤はシルデナフィル又はその製薬的に許容される形態、バルデナフィル又はその製薬的に許容される形態、タダラフィル又はその製薬的に許容される形態、或いは前記ＰＤＥ５阻害剤の二つ以上の組み合わせである、請求項１５に記載のキット。
- 前記トラマドール材料は（±）シス−トラマドール塩酸塩であり、かつ前記ＰＤＥ５阻害剤はクエン酸シルデナフィル、バルデナフィル塩酸塩、タダラフィル、或いは前記ＰＤＥ５阻害剤の二つ以上の組み合わせである、請求項１６に記載のキット。
- 前記ＰＤＥ５阻害剤はクエン酸シルデナフィルである、請求項１７に記載のキット。
- 請求項１３に記載のキットは、男性における早漏と勃起障害との併存状態を治療するためにトラマドール材料とＰＤＥ阻害剤とを使用するための指示書を更に含む、キット。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88936907P | 2007-02-12 | 2007-02-12 | |
| PCT/US2008/053710 WO2008100926A1 (en) | 2007-02-12 | 2008-02-12 | Treatment of comorbid premature ejaculation and erectile dysfunction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013264162A Division JP2014077008A (ja) | 2007-02-12 | 2013-12-20 | 併存する早漏及び勃起障害を治療するための治療剤、製薬組成物及びキット |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010518167A JP2010518167A (ja) | 2010-05-27 |
| JP2010518167A5 true JP2010518167A5 (ja) | 2012-01-26 |
Family
ID=39690490
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009549684A Pending JP2010518167A (ja) | 2007-02-12 | 2008-02-12 | 併存する早漏及び勃起障害の治療 |
| JP2013264162A Pending JP2014077008A (ja) | 2007-02-12 | 2013-12-20 | 併存する早漏及び勃起障害を治療するための治療剤、製薬組成物及びキット |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013264162A Pending JP2014077008A (ja) | 2007-02-12 | 2013-12-20 | 併存する早漏及び勃起障害を治療するための治療剤、製薬組成物及びキット |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20080262094A1 (ja) |
| EP (2) | EP2486927A1 (ja) |
| JP (2) | JP2010518167A (ja) |
| KR (3) | KR20150089085A (ja) |
| CN (1) | CN101657101B (ja) |
| AU (1) | AU2008216356C1 (ja) |
| BR (1) | BRPI0807282A2 (ja) |
| CA (1) | CA2677690C (ja) |
| DK (1) | DK2120570T3 (ja) |
| ES (1) | ES2384481T3 (ja) |
| MX (1) | MX2009008491A (ja) |
| NZ (1) | NZ579169A (ja) |
| PL (1) | PL2120570T3 (ja) |
| SG (1) | SG174079A1 (ja) |
| WO (1) | WO2008100926A1 (ja) |
| ZA (1) | ZA200906186B (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG178775A1 (en) * | 2007-02-12 | 2012-03-29 | Dmi Biosciences Inc | Reducing side effects of tramadol |
| BRPI0807282A2 (pt) * | 2007-02-12 | 2014-04-29 | Dmi Biosciences Inc | Tratamento de ejaculação precoce e disfunção erétil co-mórbidas |
| CN103263435B (zh) * | 2013-05-17 | 2014-08-13 | 宋博 | 聚维酮碘的制药用途 |
| MX369874B (es) * | 2013-11-29 | 2019-11-22 | Laboratorios Liomont S A De C V | Composicion farmaceutica para el tratamiento de la disfunción erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel. |
| WO2015134695A1 (en) * | 2014-03-07 | 2015-09-11 | Vyrix Pharmaceuticals, Inc. | Method of mitigating the side effects of a phosphodiesterase type v inhibitor in a subject |
| US20180071269A1 (en) | 2015-08-12 | 2018-03-15 | Tianxin Wang | Therapeutical methods, formulations and nutraceutical formulations |
| KR101778688B1 (ko) | 2016-05-31 | 2017-09-15 | 한양대학교 에리카산학협력단 | 포스포다이에스터라제―5 억제제를 포함하는 약제학적 복합제제 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US533669A (en) | 1895-02-05 | And conveying appaeatus | ||
| US3830934A (en) | 1967-07-27 | 1974-08-20 | Gruenenthal Chemie | Analgesic and antitussive compositions and methods |
| US3652589A (en) * | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
| US4127118B1 (en) * | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
| ATE173603T1 (de) | 1990-04-25 | 1998-12-15 | Vivus Inc | Behandlung von erektionversagen |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| US5151448A (en) | 1991-07-12 | 1992-09-29 | Crenshaw Roger T | Method for treating premature ejaculation |
| ES2120451T7 (es) * | 1991-09-06 | 2009-11-05 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Composicion que comprende un compuesto de tramadol y acetaminofeno, y su uso. |
| US5223541A (en) | 1991-09-13 | 1993-06-29 | Mcneilab, Inc. | Tramadol n-oxide material, enantiomers and compositions thereof, and their use |
| USRE36547E (en) * | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
| US5472943A (en) * | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
| US20010006967A1 (en) * | 1992-09-21 | 2001-07-05 | Stanley M. Crain | Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists |
| US6096756A (en) * | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
| US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| NZ260408A (en) * | 1993-05-10 | 1996-05-28 | Euro Celtique Sa | Controlled release preparation comprising tramadol |
| GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
| DE4329794C2 (de) * | 1993-09-03 | 1997-09-18 | Gruenenthal Gmbh | Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| US5861431A (en) | 1995-06-07 | 1999-01-19 | Iotek, Inc. | Incontinence treatment |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| US6017963A (en) | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
| DE19601744C2 (de) * | 1996-01-19 | 1998-04-16 | Gruenenthal Gmbh | Verfahren zur Herstellung der Enantiomeren von O-Demethyltramadol |
| DE19601745C1 (de) | 1996-01-19 | 1997-10-09 | Gruenenthal Gmbh | Verfahren zur Racematspaltung von Tramadol |
| IL119121A (en) * | 1996-08-22 | 2000-11-21 | Chemagis Ltd | Process for the purification of (RR-SS)-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol hydrochloride |
| US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| AU741821B2 (en) * | 1997-03-11 | 2001-12-13 | Arakis Limited | Dosage forms comprising separate portions of R- and S-enantiomers |
| WO1998046216A1 (fr) | 1997-04-11 | 1998-10-22 | Nippon Shinyaku Co., Ltd. | Traitements des mictions frequentes et de l'incontinence urinaire |
| WO1999021558A2 (en) * | 1997-10-28 | 1999-05-06 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| US6037360A (en) | 1997-10-28 | 2000-03-14 | Vivus, Incorporated | Administration of 5-HT3 receptor antagonists to treat premature ejaculation |
| US6403597B1 (en) * | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| US6548490B1 (en) * | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| IL135462A0 (en) * | 1997-11-12 | 2001-05-20 | Bayer Ag | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| US6375957B1 (en) * | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| EP1041988A4 (en) * | 1997-12-22 | 2002-03-13 | Euro Celtique Sa | METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS |
| ES2412409T3 (es) * | 1997-12-22 | 2013-07-11 | Euro-Celtique S.A. | Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo |
| US6339826B2 (en) * | 1998-05-05 | 2002-01-15 | International Business Machines Corp. | Client-server system for maintaining a user desktop consistent with server application user access permissions |
| US6156342A (en) * | 1998-05-26 | 2000-12-05 | Andex Pharmaceuticals, Inc. | Controlled release oral dosage form |
| US6403605B1 (en) * | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
| US6339106B1 (en) * | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
| US6476078B2 (en) * | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
| US6331571B1 (en) * | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
| US6943166B1 (en) | 1999-04-30 | 2005-09-13 | Lilly Icos Llc. | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
| US6765010B2 (en) * | 1999-05-06 | 2004-07-20 | Pain Therapeutics, Inc. | Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
| US20030055070A1 (en) * | 1999-07-01 | 2003-03-20 | Wilma Harrison | Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction |
| US6821975B1 (en) * | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| US6451806B2 (en) * | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
| WO2001034125A2 (en) * | 1999-11-09 | 2001-05-17 | Darwin Discovery Limited | Therapeutic use and formulation of (-)-tramadol |
| US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| US20020091129A1 (en) * | 2000-11-20 | 2002-07-11 | Mitradev Boolell | Treatment of premature ejaculation |
| EP1397126B9 (en) * | 2001-03-16 | 2007-02-21 | DMI Biosciences, Inc. | Use of tramadol for delaying ejaculation |
| WO2002092059A1 (en) * | 2001-05-11 | 2002-11-21 | Endo Pharmaceuticals, Inc. | Abuse-resistant opioid dosage form |
| DK1414451T3 (da) * | 2001-08-06 | 2009-08-10 | Euro Celtique Sa | Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist |
| US7019010B2 (en) * | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| WO2003042216A1 (en) * | 2001-11-09 | 2003-05-22 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
| WO2004069167A2 (en) * | 2003-01-31 | 2004-08-19 | Nastech Pharmaceutical Company Inc. | Method and compositions for treating male infertility |
| US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| US20050054688A1 (en) * | 2003-08-08 | 2005-03-10 | Pfizer Inc | Selective serotonin reuptake inhibitors in the treatment of disease |
| US20060149480A1 (en) * | 2004-02-26 | 2006-07-06 | Lundeen James E | Method of making combination medicament and medicament made thereby |
| US7483535B2 (en) * | 2004-09-15 | 2009-01-27 | Hewlett-Packard Development Company, L.P. | Transmission of generalized scalable bit-streams |
| WO2007070779A2 (en) * | 2005-12-13 | 2007-06-21 | Trinity Laboratories, Inc. | A method to treat premature ejaculation in humans |
| US20070185145A1 (en) * | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
| BRPI0807282A2 (pt) * | 2007-02-12 | 2014-04-29 | Dmi Biosciences Inc | Tratamento de ejaculação precoce e disfunção erétil co-mórbidas |
| SG178775A1 (en) * | 2007-02-12 | 2012-03-29 | Dmi Biosciences Inc | Reducing side effects of tramadol |
| US20100120780A1 (en) * | 2007-04-19 | 2010-05-13 | Chandra Ulagaraj Singh | Treatments for premature ejaculation in humans |
-
2008
- 2008-02-12 BR BRPI0807282-5A2A patent/BRPI0807282A2/pt not_active IP Right Cessation
- 2008-02-12 PL PL08729644T patent/PL2120570T3/pl unknown
- 2008-02-12 SG SG2011058682A patent/SG174079A1/en unknown
- 2008-02-12 KR KR1020157017473A patent/KR20150089085A/ko not_active Ceased
- 2008-02-12 AU AU2008216356A patent/AU2008216356C1/en not_active Ceased
- 2008-02-12 CN CN2008800118025A patent/CN101657101B/zh not_active Expired - Fee Related
- 2008-02-12 KR KR1020147007397A patent/KR20140054312A/ko not_active Ceased
- 2008-02-12 WO PCT/US2008/053710 patent/WO2008100926A1/en not_active Ceased
- 2008-02-12 US US12/029,783 patent/US20080262094A1/en not_active Abandoned
- 2008-02-12 EP EP12167624A patent/EP2486927A1/en not_active Withdrawn
- 2008-02-12 EP EP08729644A patent/EP2120570B1/en active Active
- 2008-02-12 JP JP2009549684A patent/JP2010518167A/ja active Pending
- 2008-02-12 MX MX2009008491A patent/MX2009008491A/es active IP Right Grant
- 2008-02-12 NZ NZ579169A patent/NZ579169A/en not_active IP Right Cessation
- 2008-02-12 DK DK08729644.8T patent/DK2120570T3/da active
- 2008-02-12 ES ES08729644T patent/ES2384481T3/es active Active
- 2008-02-12 KR KR1020097018878A patent/KR20090121315A/ko not_active Ceased
- 2008-02-12 CA CA2677690A patent/CA2677690C/en not_active Expired - Fee Related
-
2009
- 2009-09-07 ZA ZA2009/06186A patent/ZA200906186B/en unknown
-
2011
- 2011-09-28 US US13/247,347 patent/US20120022071A1/en not_active Abandoned
- 2011-09-28 US US13/247,387 patent/US20120018345A1/en not_active Abandoned
-
2013
- 2013-12-20 JP JP2013264162A patent/JP2014077008A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010518168A5 (ja) | ||
| JP2010518167A5 (ja) | 併存する早漏及び勃起障害を治療するための治療剤、製薬組成物及びキット | |
| CA2677691A1 (en) | Reducing side effects of tramadol | |
| WO2012005500A3 (ko) | 다폭세틴을 포함하는 시간차 서방출 경구투여형 약학적 조성물 | |
| RU2009120988A (ru) | Применение 3-альфа-андростендиола, необязательно в сочетании с ингибитором фосфодиэстеразы 5, при лечении половой дисфункции | |
| TW200626159A (en) | Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor | |
| CY1114448T1 (el) | Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας | |
| WO2005120461A3 (en) | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof | |
| WO2014027975A3 (en) | Novel orally administered pharmaceutical formulations | |
| WO2008011335A3 (en) | Metal binding compounds, metal binding compositions, and their uses | |
| CA2677690A1 (en) | Treatment of comorbid premature ejaculation and erectile dysfunction | |
| NO20076219L (no) | Farmasoytisk formulering med apomorfin for bukkal administrering | |
| WO2007146124A3 (en) | Deuterated tadalafil derivatives | |
| WO2004005324A3 (en) | Peptide composition for treatment of sexual dysfunction | |
| WO2008070313A3 (en) | 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use | |
| WO2018060463A3 (en) | Treatment of prostate cancer | |
| HRP20131233T1 (hr) | Terapeutski sastav koji obuhvaä†a specifiäśni antagonist receptora endotelina i pde5-inhibitor | |
| WO2014027981A3 (en) | Effervescent tablet formulations of dapoxetine and a pde5 inhibitor | |
| WO2008070010A3 (en) | Hydroxylamine derivatives for the treatment of stroke | |
| JP2009518415A5 (ja) | ||
| SG153661A1 (en) | Formulation and methods for the treatment of thrombocythemia | |
| WO2007113243A3 (en) | Use of pde 5 inhibitors for the treatment of overactive bladder | |
| WO2008037045A3 (en) | Composition containing a mixture of antidepressants for treating premature ejaculation. | |
| NO20062883L (no) | Fosfodiesterase-V-inhibitorpreparater | |
| JP2012102085A5 (ja) |